takeda pharmaceutical co

Takeda Receives NDA Approval For Gastric Ulcer And Hypertension Drugs

Takeda's two new fixed dose combination drugs, TAKELDA® and Zacras®, receive approval from the Japanese Ministry of Health, Labor and Welfare.

Takeda’s ADCETRIS® Approved For Lymphoma Treatment In Japan

Takeda's ADCETRIS® has been approved for the treatment of patients with certain types of lymphoma in Japan.

Takeda To Sell BIKEN’s Chickenpox Vaccine

Takeda has announced a sales agreement with BIKEN to commence the sale of BIKEN's chickenpox vaccine in Japan from February 2014.

Takeda Submits New Drug Application For Fomepizole

Takeda has submitted an NDA to the Japanese Ministry of Health, Labor and Welfare for fomepizole, a treatment for ethylene glycol and methanol poisonings.

Takeda, MMV Partner To Study Anti-Malarial Compounds

Takeda Pharma will collaborate with Medicines for Malaria Venture to study two new anti-malarial compounds.

Takeda Terminates Development Of Fasiglifam

Takeda has decided to terminate the development activities for fasiglifam, an investigational treatment for type II diabetes, due to concerns about liver safety.

Oral Proteasome Inhibitor Could Improve Multiple Myeloma Treatment

Takeda has announced clinical study results combining oral investigational MLN9708 with lenalidomide and dexamethasone, in patients with newly diagnosed multiple myeloma.

Teva, Takeda To Commercialize Multiple Sclerosis Drug

Teva and Takeda will jointly commercialize Teva’s glatiramer acetate formulation for the treatment of multiple sclerosis in Japan.

Takeda’s Oral Proteasome Inhibitor MLN9708 Enters Ph III Study In Japan

Takeda has initiated enrollment of patients in Japan in an ongoing global Phase III clinical study of its novel oral proteasome inhibitor MLN9708.